Autolus Therapeutics PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals

London, april 24, 2024 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), a clinical-stage biopharmaceutical company developing next-generation programmed t cell therapies, today announces that the abstract for longer-term follow-up and additional data analysis from the pivotal phase 2 felix study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult b-cell acute lymphoblastic leukemia (all) was selected for an oral presentation at the 2024 american society of clinical oncology (asco) annual meeting, (may 31 – june 4, 2024, chicago). asco oral presentation, abstract #6504: title: obecabtagene autoleucel (obe-cel, auto1) in adults with relapsed/refractory b-cell acute lymphoblastic leukemia (r/r b-all): overall survival (os), event-free survival (efs) and the potential impact of chimeric antigen receptor (car)-t cell persistency and the potential impact of chimeric antigen receptor (car)-t cell persistency and consolidative stem cell transplantation (sct) in the open-label, single-arm felix phase ib/ii study session title: oral abstract session – hematologic malignancies—leukemia, myelodysplastic syndromes, and allotransplant session date and time: friday, may 31, 2024, 14:45 – 17:45 edt, 19:45 – 22:45 bst presenting author: dr elias jabbour, professor, department of leukemia, division of cancer medicine, md anderson cancer center, houston, tx a conference call and webcast to discuss the presented data will be held at 9:30 am edt/2:30 pm bst on saturday june 1, 2024.

London, april 23, 2024 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), a clinical-stage biopharmaceutical company developing next-generation programmed t cell therapies, today announced that it will release its first quarter 2024 financial results and operational highlights before open of us markets on tuesday, may 14, 2024. management will host a conference call and webcast at 8:30 am edt/1:30 pm bst to discuss the company's financial results and provide a general business update.

London, april 01, 2024 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), a clinical-stage biopharmaceutical company developing next-generation programmed t cell therapies, today announces the appointment of mike bonney as chairman of the board, and ravi rao m.d., as non-executive director.

Announced strategic collaboration and equity investment from biontech for aggregate proceeds of $250 million upfront, plus underwritten offering of adss for $350 million, for gross proceeds of $600 million received in february 2024 submitted a biologics license application (bla) for obecabtagene autoleucel (obe-cel), a potentially transformational treatment for relapsed/refractory (r/r) adult b-cell acute lymphoblastic leukemia (all), to the us food & drug administration (fda); prescription drug user fee act (pdufa) target action date november 16, 2024 successfully completed first facility inspection and obtained a manufacturer's importation authorization (mia) from the medicines and healthcare products regulatory agency (mhra), enabling the commercial product supply for obe-cel at the nucleus manufacturing facility submitted a market authorization application (maa) for obe-cel in r/r adult all with the european medicines agency (ema) conference call to be held today at 08:30 am edt/12:30 pm gmt: conference call participants should pre-register using the link at the bottom of this press release london, march 14, 2024 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), a clinical-stage biopharmaceutical company developing next-generation programmed t cell therapies, today announced its operational and financial results for the full year ended december 31, 2023...

London, march 12, 2024 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), a clinical-stage biopharmaceutical company developing next-generation programmed t cell therapies, today announces that following the most recent gmp inspection by the mhra in february 2024, autolus' nucleus manufacturing facility in stevenage has obtained a manufacturer's importation authorisation (mia) together with the accompanying gmp certificate. this authorisation enables autolus to manufacture for global commercial and clinical product supply from the nucleus effective as of march 18, 2024.

LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it will release its fourth quarter and full year 2023 results and operational highlights on Thursday March 14, 2024. Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company's financial results and provide a general business update.

Autolus Therapeutics PLC Sponsored ADR (AUTL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Obe-cel continues to demonstrate comparative efficacy with fewer side effects to approved therapies. Thus, the company will likely gain its first market authorization in November. Autolus made several strong leadership hires with direct experience in M&A, oncology, and lupus, a new research area.

January's payrolls report shows 353,000 jobs

Autolus Therapeutics is developing cell-based immunotherapy for cancer, focusing on CD19 in ALL. Their flagship product, obe-cel, has shown promising results in treating relapsed/refractory B-cell ALL with reduced toxicities compared to other CAR T-cell therapies. Autolus Therapeutics also has a dual-targeted BCMA/CD19 CAR T-cell therapy called AUTO8, which has shown positive responses in patients with relapsed/refractory multiple myeloma.

LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November. Truist Securities BioPharma Symposium Panel : Considerations for an Oncology Company's Autoimmune Side Hustle Date and time: 9 November 2023, 11:40am ET / 16:40pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Jefferies London Healthcare Conference   Fireside Chat Date and time: 16 November 2023, 4:00am ET / 9:00am GMTLocation: London, UKPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Piper Sandler 35th Annual Healthcare Conference Fireside Chat Date and time: 28 November 2023, 11:30am ET/ 16:30pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Find out more information about upcoming events and any webcast and replay details at: https://www...

Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Company Participants Julia Wilson – Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Matthew Phipps – William Blair Dev Prasad – Jefferies Gil Blum – Needham and Company Yanan Zhu – Wells Fargo Karina Rabayeva – Truist Simon Baker – Redburn Atlantic Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Third Quarter 2023 Financial Results Conference Call and Business Update. At this time, all participants are in listen-only mode.

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company's financial results and provide a general business update.

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company's financial results and provide a general business update.

Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Dr. Christian Itin - CEO Dr. Lucinda Crabtree - CFO Rob Dolski - incoming CFO Julia Wilson - IR Conference Call Participants Matt Phipps - William Blair Asthika Goonewardene - Truist Financial Kelly Shi - Jefferies Noah Burhance - J.P. Morgan Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Second Quarter 2023 Financial Results Conference.